Immune Cell Conjugates and Methods for Producing and Using the Same
Summary
Sandigene Inc. has published US Patent Application US20260108621A1, filed October 16, 2025 under Application No. 19360236, covering surface-modified immune cells with covalently bound linkers and non-antibody ligands selective to target-cell receptors. The application names Yanwen Fu, Reyna Koreen V. Lim, Changyou Lin, and Moli Liu as inventors. The patent covers applications in anticancer therapeutics (CPC: A61P 35/00) and cell production methods (CPC: C12N 5/0006).
“The present disclosure provides a surface modified immune cell comprising (i) a linker that is covalentiy bound to an immune cell surface and (ii) a non-antibody ligand covalently bound to said linker, wherein said ligand is selective to a receptor that is present in a target cell.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
Sandigene Inc. has published US Patent Application US20260108621A1 covering surface-modified immune cells and methods for their production and use. The application claims a linker covalently bound to an immune cell surface, with a non-antibody ligand also covalently bound to the linker, where the ligand selectively targets receptors present in target cells — primarily for anticancer therapeutic applications.
For pharmaceutical and biotech firms developing cell-based immunotherapies or targeted conjugate treatments, this published application signals potential future freedom-to-operate considerations in the immune cell modification space. Competitors active in covalent cell-surface engineering or non-antibody ligand targeting should review the claimed scope for potential overlap with existing or planned programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Immune Cell Conjugates and Methods for Producing and Using the Same
Application US20260108621A1 Kind: A1 Apr 23, 2026
Assignee
Sandigene Inc.
Inventors
Yanwen FU, Reyna Koreen V. Lim, Changyou Lin, Moli Liu
Abstract
The present disclosure provides a surface modified immune cell comprising (i) a linker that is covalentiy bound to an immune cell surface and (ii) a non-antibody ligand covalently bound to said linker, wherein said ligand is selective to a receptor that is present in a target cell. The present disclosure also provides a method for producing and using the same.
CPC Classifications
A61K 47/6901 A61P 35/00 C12N 5/0006
Filing Date
2025-10-16
Application No.
19360236
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.